Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANCRIT-1: 90Y-Clivatuzumab Tetraxetan in Metastatic Pancreatic Cancer
NCT01956812Phase 3Terminated
- Sponsor
- Gilead Sciences
- Start
- Dec 2013
- Primary completion
- Nov 2016
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 3 trial of clivatuzumab tetraxetan in pancreatic adenocarcinoma (PDAC), sponsored by Gilead Sciences. Started Dec 2013; status: terminated.
02
Drugs
clivatuzumab tetraxetan
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT01956812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01956812.